BICO News Feed​

Discover the latest news from our business areas.
  • 10:10 am

Unlocking the Future of Medicine: The Promise and Techniques of Allogeneic Stem Cell Therapies

Share on facebook
Share on twitter
Share on linkedin
  • icon-time-svg

Unlocking the Future of Medicine: The Promise and Techniques of Allogeneic Stem Cell Therapies

Picture of By Fernando Aprile García

By Fernando Aprile García

Head of Applications

Stem cell technologies are responsible for some of the most exciting areas of modern healthcare. A core element of this is the use of allogeneic stem cell therapy in regenerative medicine. These therapies use donor-derived somatic cells, which are dedifferentiated into induced pluripotent stem cells (iPSC). From here, iPSCs can be differentiated into virtually any cell type to replace damaged or dead tissue in patients1. The production process is complex, but new technologies in areas like automation are helping researchers overcome long-standing challenges2. This article covers the exciting potential of allogeneic stem cell therapy, how they are generated, and how automation is streamlining their production and advancing the next generation of iPSC-based therapies (Fig. 1).

Figure 1. Stem cell therapy is used to treat conditions like neurodegenerative and cardiovascular disease.

Therapeutic Potential of Allogeneic Stem Cell Therapy

Stem cell therapies have the potential to treat a wide range of diseases, especially in the field of regenerative medicine1. They also have critical applications in research and development.

  • Disease Modeling – The versatility of iPSC techniques makes them fantastic for generating models of a massive range of diseases3. Furthermore, they can be genetically modified to express disease-associated genetic variants4.
  • Drug Discovery – iPSCs are used to generate cells that more closely resemble disease conditions, enabling more accurate testing of potential drugs5. For instance, iPSCs can be differentiated into neurons and modified to express genetic variants associated with Alzheimer’s disease6. Researchers can use these cells in high-throughput assays to test how potential drugs affect the disease mechanisms and neuronal function.

Medicine

iPSC-derived allogeneic cell therapies hold great promise in personalized medicine. They allow donor cells to be transformed into various cell types and engineered to avoid immune rejection. This adaptability makes them valuable for regenerative medicine, offering potential treatments for diseases like heart disease (cardiomyocytes) and diabetes (pancreatic β-cells)1,4.

Advantages

  • Universality – Allogeneic stem cell therapy can theoretically be given to any individual, making them an “off-the-shelf” solution for several diseases for which there is an urgent medical need7.
  • Scalability – Their universality makes these cells suitable for large-scale production, leading to cost savings and improved standardization8.

Challenges

  • Immune Rejection – While these cells are often modified to overcome immune rejection, it remains challenging to apply them as therapies in some instances9.
  • Tumorigenicity – iPSC-based therapies can carry a risk of tumor development in patients, though this can also be reduced via genetic modifications10.
  • Cost – These therapies are relatively expensive to produce, though allogeneic therapies benefit from economies of scale that autologous therapies do not11.

We have only scratched the surface of how allogeneic stem cells can transform regenerative medicine. For a more detailed discussion read our full article on this topic.

Core Methods

Generating iPSC-based allogeneic cell therapies is a long and complicated process, and researchers must overcome many challenges and potential pitfalls to produce a high quality stem cell therapy.

Process

  • Reprogramming and Modification – Somatic cells are dedifferentiated to a pluripotent state by the addition of transcription factors known collectively as Yamanaka factors12.
  • Selection – Single iPSCs are seeded into individual wells to facilitate the growth of monoclonal populations. The UP.SIGHT from CYTENA provides gentle dispensing and >97% single-cell dispensing efficiency. This application note demonstrates how the UP.SIGHT addresses common challenges in iPSC dispensing and cultivation.
  • Quality Control (QC) – Robust QC processes control for potential issues like loss of pluripotency, contamination, and genomic instability. QC is performed throughout the development process13.
  • Scaling – Scaling up occurs both at the iPSC stage and after iPSCs have been differentiated so there is a stock of differentiated cells ready for clinical use.
  • Storing – iPSCs are typically cryopreserved at 196°C with intermediate cooling steps14. Improper storage can affect downstream function.

Therapy Success Story - Aloficel

Crohn’s is a chronic inflammatory disease that can lead to the development of perianal fistulas, which are abnormal tunnel-like connections between the rectum or anus and the surrounding skin. Perianal fistulas cause symptoms, including pain, discharge, and recurring infections15. Aloficel is an allogeneic stem cell therapy that uses mesenchymal stem cells derived from the adipose tissue of adult donors. It is now approved for use in the EU and  Japan and is administered during surgery to help reduce inflammation and repair damaged tissue16,17. Aloficel demonstrates the power of allogeneic stem cell therapies in tackling challenging conditions that have historically been difficult to manage.

Future Technologies

3D printing technologies allow iPSCs to be integrated into biomaterials and organoids, providing better disease models and functional cell-based therapeutics for tissue regeneration. Organoids are particularly promising for use in the early stages of drug development to better recapitulate complex diseases (Fig. 2)18.

Figure 2. Organoids offer a more realistic model for disease than monoclonal cell lines.

For more information on how iPSC-based therapies are produced and the associated challenges, read our full article, which covers these topics in more detail.

Benefits of Automation in iPSC Therapy Production

Automation confers numerous benefits that streamline production and enhance the quality of the final product. 

Efficiency and Scale

When performed manually, single-cell seeding is prone to errors, contamination, and time loss, which slows development. Automated processes, such as those that incorporate the UP.SIGHT from CYTENA, provide faster cell seeding and a >99.99% probability of clonal derivation. Automation also supports resource efficiency by allowing workflows to be scaled down19.

Higher Throughput

Liquid handlers that use automation can dispense cells and media more accurately and quickly than manual methods. This means more cells can be seeded in the same workflow. When coupled with dedicated software like CYTENA’s C.STUDIO, automation makes it simple to screen thousands of clones and identify the best ones to proceed with.

Regulatory Compliance

Regulatory bodies require proof of monoclonality before approving cell-based therapies11. The UP.SIGHT from CYTENA possesses dual imaging capabilities that image single cells as they are dispensed and after they settle in the well, helping researchers side-step common regulatory pitfalls in cell therapy development (Fig. 3).

Figure 3. The UP.SIGHT makes it easy to prove monoclonality to regulators and gives researchers confidence in their cell line development workflows.

For more information on this topic, including how automation reduces the risk of contamination and improves workflow reliability, read our full-length article.

Conclusion

Allogeneic stem cell therapy holds immense promise in transforming regenerative medicine and drug discovery. By leveraging iPSCs, these therapies offer versatile solutions for treating various diseases. We created a tracker to monitor the cell and gene therapy pipeline, highlighting clinical trial progress and regulatory approvals. Automation helps researchers overcome common hurdles in therapy development by streamlining production processes, improving efficiency, and facilitating regulatory compliance. As technology advances, the future of allogeneic stem cell therapies is becoming even brighter, opening up new opportunities for personalized medicine and large-scale treatments.

CYTENA’s suite of high-end instrumentation supports ambitious researchers striving to produce the next generation of regenerative medicines. Contact our team to learn more about the UP.SIGHT single cell dispenser. Book a demo to explore its capabilities first hand.

References

  1. Aboul-Soud MAM, Alzahrani AJ, Mahmoud A. Induced Pluripotent Stem Cells (iPSCs)-Roles in Regenerative Therapies, Disease Modelling and Drug Screening. Cells. 2021;10(9):2319. doi:10.3390/cells10092319
  2. Doulgkeroglou MN, Di Nubila A, Niessing B, et al. Automation, Monitoring, and Standardization of Cell Product Manufacturing. Front Bioeng Biotechnol. 2020;8:811. doi:10.3389/fbioe.2020.00811
  3. Liu C, Oikonomopoulos A, Sayed N, Wu JC. Modeling human diseases with induced pluripotent stem cells: from 2D to 3D and beyond. Development. 2018;145(5):dev156166. doi:10.1242/dev.156166
  4. Nicholson MW, Ting CY, Chan DZH, et al. Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy. Cells. 2022;11(11):1853. doi:10.3390/cells11111853
  5. Elitt MS, Barbar L, Tesar PJ. Drug screening for human genetic diseases using iPSC models. Human Molecular Genetics. 2018;27(R2):R89-R98. doi:10.1093/hmg/ddy186
  6. Penney J, Ralvenius WT, Tsai LH. Modeling Alzheimer’s disease with iPSC-derived brain cells. Mol Psychiatry. 2020;25(1):148-167. doi:10.1038/s41380-019-0468-3
  7. González BJ, Creusot RJ, Sykes M, Egli D. How Safe Are Universal Pluripotent Stem Cells? Cell Stem Cell. 2020;26(3):307-308. doi:10.1016/j.stem.2020.02.006
  8. Jha BS, Farnoodian M, Bharti K. Regulatory considerations for developing a phase I investigational new drug application for autologous induced pluripotent stem cells-based therapy product. Stem Cells Transl Med. 2021;10(2):198-208. doi:10.1002/sctm.20-0242
  9. Petrus-Reurer S, Romano M, Howlett S, Jones JL, Lombardi G, Saeb-Parsy K. Immunological considerations and challenges for regenerative cellular therapies. Commun Biol. 2021;4(1):798. doi:10.1038/s42003-021-02237-4
  10. Sato Y, Bando H, Di Piazza M, et al. Tumorigenicity assessment of cell therapy products: The need for global consensus and points to consider. Cytotherapy. 2019;21(11):1095-1111. doi:10.1016/j.jcyt.2019.10.001
  11. McKenna DH, Perlingeiro RCR. Development of allogeneic iPS cell-based therapy: from bench to bedside. EMBO Mol Med. 2023;15(2):e15315. doi:10.15252/emmm.202115315
  12. Cerneckis J, Cai H, Shi Y. Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications. Sig Transduct Target Ther. 2024;9(1):112. doi:10.1038/s41392-024-01809-0
  13. Madrid M, Lakshmipathy U, Zhang X, et al. Considerations for the development of iPSC-derived cell therapies: a review of key challenges by the JSRM-ISCT iPSC Committee. Cytotherapy. Published online June 2024:S1465324924007308. doi:10.1016/j.jcyt.2024.05.022
  14. Yuan Y, Yang Y, Tian Y, et al. Efficient long-term cryopreservation of pluripotent stem cells at −80 °C. Sci Rep. 2016;6(1):34476. doi:10.1038/srep34476
  15. Lee JL, Yoon YS, Yu CS. Treatment Strategy for Perianal Fistulas in Crohn Disease Patients: The Surgeon’s Point of View. Ann Coloproctol. 2021;37(1):5-15. doi:10.3393/ac.2021.02.08
  16. Mezey É. Human Mesenchymal Stem/Stromal Cells in Immune Regulation and Therapy. Stem Cells Translational Medicine. 2022;11(2):114-134. doi:10.1093/stcltm/szab020
  17. Takeda Receives Approval to Manufacture and Market Alofisel®▼ (darvadstrocel) in Japan for Treatment of Complex Perianal Fistulas in Patients with Non-active or Mildly Active Luminal Crohn’s Disease. Accessed September 30, 2024. https://www.takeda.com/newsroom/newsreleases/2021/takeda-receives-approval-to-manufacture-and-market-alofisel-darvadstrocel-in-japan-for-treatment-of-complex-perianal-fistulas-in-patients-with-non-active-or-mildly-active-luminal-crohns-disease/
  18. Soman SS, Vijayavenkataraman S. Applications of 3D Bioprinted-Induced Pluripotent Stem Cells in Healthcare. Int J Bioprint. 2020;6(4):280. doi:10.18063/ijb.v6i4.280
  19. 19. Holland I, Davies JA. Automation in the Life Science Research Laboratory. Front Bioeng Biotechnol. 2020;8(571777). doi:10.3389/fbioe.2020.571777

More news

September 23, 2024 | Cytena

Unlocking the Future of Medicine: The Promise and Techniques of Allogeneic Stem Cell Therapies
September 16, 2024 | Cytena

Automation in iPSC-based Cell Therapy Generation: Increasing Efficiency and Consistency
September 9, 2024 | Cytena

Allogeneic iPS Cell‐based Therapy: Key Techniques and Methods
September 3, 2024 | Bico

MatTek Life Sciences Licenses Cutting-Edge In Vitro Human Tissue Technology to Leading Production Laboratory in China
August 1, 2024 | Cellenion

Scale up your single cell proteomics to thousands of cells with nPOP
June 17, 2024 | Bico

Charles River Laboratories, in Collaboration With MatTek Life Sciences, Awarded Grant from the Foundation for Chemistry Research and Initiatives to Advance Research Alternatives
June 4, 2024 | Bico

BICO Welcomes Ryan Bagley as the new CEO of Discover ECHO
May 13, 2024 | Cellenion

Find us at Booth #138 at ASMS US – Anaheim, CA
March 19, 2024 | Scienion

sciFLEXARRAYER User Training in Berlin
Load more